Share:
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.